CD44 VARIANT ISOFORMS IN NON-HODGKINS-LYMPHOMA - A NEW INDEPENDENT PROGNOSTIC FACTOR

被引:225
作者
STAUDER, R [1 ]
EISTERER, W [1 ]
THALER, J [1 ]
GUNTHERT, U [1 ]
机构
[1] UNIV INNSBRUCK HOSP, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA
关键词
D O I
10.1182/blood.V85.10.2885.bloodjournal85102885
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Isoforms of the transmembrane glycoprotein CD44, generated by alternative RNA splicing, have been correlated to tumor dissemination, For evaluation of the potential role of CD44 variant isoforms in non-Hodgkin's lymphoma (NHL), the presence of CD44 isoforms was analyzed in a large panel of reactive and neoplastic lymphoid tissues by immunohistochemical staining, as well as detection of CD44 variant RNAs by the reverse transcriptase-polymerase chain reaction. Whereas the CD44 standard or hematopoietic isoform (CD44s), devoid of the variant regions, was expressed in all leukocyte subpopulations, the variant isoforms (CD44v) showed a highly restricted pattern of expression, mainly observed in epithelial layers of lymphoid tissues and subpopulations of leukocytes after stimulation. In addition to a strong expression of CD44s, variant isoforms containing CD44-6v in combination with other variant exons were observed predominantly in aggressive lymphoma and were associated with a shorter overall survival of patients (n = 138; P <.0001). Moreover, multivariate analysis indicated CD44-6v as a new independent prognostic parameter in high grade NHL in comparison with the risk groups defined by the International NHL Lymphoma Prognostic Factors Project (N Engl J Med 329:987, 1993). (C) 1995 by The American Society of Hematology.
引用
收藏
页码:2885 / 2899
页数:15
相关论文
共 65 条
[1]   PARTICIPATION IN NORMAL IMMUNE-RESPONSES OF A METASTASIS-INDUCING SPLICE VARIANT OF CD44 [J].
ARCH, R ;
WIRTH, K ;
HOFMANN, M ;
PONTA, H ;
MATZKU, S ;
HERRLICH, P ;
ZOLLER, M .
SCIENCE, 1992, 257 (5070) :682-685
[2]   CD44 IS NECESSARY FOR OPTIMAL CONTACT ALLERGIC RESPONSES BUT IS NOT REQUIRED FOR NORMAL LEUKOCYTE EXTRAVASATION [J].
CAMP, RL ;
SCHEYNIUS, A ;
JOHANSSON, C ;
PURE, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :497-507
[3]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[4]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[5]   IMMUNOENZYMATIC LABELING OF MONOCLONAL-ANTIBODIES USING IMMUNE-COMPLEXES OF ALKALINE-PHOSPHATASE AND MONOCLONAL ANTI-ALKALINE PHOSPHATASE (APAAP COMPLEXES) [J].
CORDELL, JL ;
FALINI, B ;
ERBER, WN ;
GHOSH, AK ;
ABDULAZIZ, Z ;
MACDONALD, S ;
PULFORD, KAF ;
STEIN, H ;
MASON, DY .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1984, 32 (02) :219-229
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]  
DIGHIERO G, 1991, BLOOD, V78, P1901
[8]  
DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P739
[9]   CD44 AND ITS ROLE IN TUMOR PROGRESSION AND METASTASIS [J].
EAST, JA ;
HART, IR .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (14) :1921-1922
[10]   PROSPECTIVE MULTICENTER TRIAL FOR THE RESPONSE-ADAPTED TREATMENT OF HIGH-GRADE MALIGNANT NON-HODGKINS-LYMPHOMAS - UPDATED RESULTS OF THE COP-BLAM/IMVP-16 PROTOCOL WITH RANDOMIZED ADJUVANT RADIOTHERAPY [J].
ENGELHARD, M ;
MEUSERS, P ;
BRITTINGER, G ;
BRACK, N ;
DORNOFF, W ;
ENNE, W ;
GASSMANN, W ;
GERHARTZ, H ;
HALLEK, M ;
HEISE, J ;
HETTCHEN, W ;
HUHN, D ;
KABELITZ, K ;
KUSE, R ;
LENGFELDER, E ;
LUDWIG, F ;
MEUTHEN, I ;
RADTKE, H ;
SCHADECK, C ;
SCHOBER, C ;
SCHUMACHER, E ;
SIEGERT, W ;
STAIGER, HJ ;
TERHARDT, E ;
THIEL, E ;
THOMAS, M ;
WAGNER, T ;
WILLEMS, MG ;
WILMANNS, W ;
ZWINGERS, T ;
STEIN, H ;
TIEMANN, M ;
LENNERT, K .
ANNALS OF ONCOLOGY, 1991, 2 :177-180